JUN and colorectal carcinoma: Moreover, combined treatment of SFN and polyphenol (-) epigallocatechin-3-gallate (EGCG) culminated the synergistic activation of the transcription factor, activator protein-1 (AP-1), and reduction in cyclin-D1 expression, thereby reducing cell viability of HT-29 CRC cells [93].